← Human Trials & Peer-Reviewed Studies
Effect of Vitamin D and/or Marine n-3 Fatty Acid Supplementation on Changes in Migraine Frequency and Severity.
Plain-language guide to PMID 33444588 (2021): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, migraine.
Key Facts
- PMID
- 33444588
- Journal
- The American journal of medicine
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Rist PM et al. (5 authors)
- DOI
- 10.1016/j.amjmed.2020.11.023
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of migraine.
The researchers used χ2 tests to compare proportions of individuals reporting changes in migraine frequency and severity between active and placebo groups.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
Lifetime history of migraine was assessed a median of 4.6 years after the start of the trial.
Individuals were asked to self-report changes in migraine frequency (no change, more frequent, or less frequent) and severity (no change, more severe, less severe) in the past 5 years.
What Was Measured
The subject headings attached to it are Fatty Acids, Omega-3, Incidence, Migraine Disorders, Pain, Surveys and Questionnaires and Vitamin D.
The authors tagged it with the keywords Migraine Omega-3 fatty acids.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with migraine.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (The American journal of medicine), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Migraine research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.